ERBB2 and neoplasm: BM was also found to harbour genetic changes that were not detected in the primary tumour, including actionable mutations that were eligible for targeted therapy although, beyond HER2 and oestrogen receptor (ER) status, the therapeutic implication(s) of such mutations remain to be established.13